TTP Labtech purchases life science assets from AssayMetrics

TTP Labtech has announced the purchase of several strategically important assets from AssayMetrics, a life science company based in Cardiff.

The purchase of these new fluorescence lifetime technology (FLT) offerings will strengthen the company's position in this increasingly important field. Scientists have increasingly come to see FLT as a key cost-effective screening technology option.

Existing offerings in TTP Labtech's FLT range include the new Ameon system, which has been licensed from Fluorescence Innovations and is equipped with real-time decay curve analysis tools, offering speed, precision and data quality benefits.

FLT has gained prominence in recent times thanks to significant improvements in assay reagents and the expanded availability of high-throughput screen-compatible readers.

Dr Wayne Bowen, chief scientific officer of TTP Labtech, said: "Increasing access to relevant instrumentation is revealing the true potential of FLT for cost critical assays to the screening community."

TTP Labtech is a Cambridge-based developer and manufacturer of high-quality automated laboratory equipment. It has experienced considerable growth and success in the last two years.